Gilead Sciences, Inc.
333 Lakeside Drive
Tel: 800-GILEAD-5 or 650-574-3000
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
Please click here for clinical trial information.
1244 articles with Gilead Sciences, Inc.
Federal court judge orders Merck to repay $2.5 Billion to Gilead in overturned patent decision.
2/15/2018Investors and analysts had been encouraging Gilead to acquire something for a long time, so they were mostly happy when it bought Kite Pharma in September.
Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21
Gilead Sciences announced that Norbert W. Bischofberger, PhD, Gilead’s Executive Vice President, R&D and Chief Scientific Officer, and Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2018 Global Healthcare Conference in New York on Wednesday, February 21 at 9:00 a.m. Eastern Time.
The company's management has a lot on its plate in 2018.
The FDA approved Gilead's triple combination treatment for HIV, Biktarvy.
Total revenues for the fourth quarter of 2017 were $5.9 billion compared to $7.3 billion for the same period in 2016.
She previously served on Gilead’s Scientific Advisory Board from 1989 to 2007.
Sometimes the biggest are also the best. That's the case for biotherapeutics stocks.
Here is a look at a few important regulatory events scheduled for the month of February.
A look at three big biotech companies that have big catalysts this year that could have a, you guessed it, big effect.
This is a market like the world has never seen.
Gilead Sciences to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 6, 2018
Gilead Sciences, Inc. announced today that its fourth quarter and full year 2017 financial results will be released on Tuesday, February 6, after the market closes.
The latest acquisition makes it the highest amount paid for a flex R&D building in Los Angeles County.
These stocks have been given a Strong Buy or Buy rating by 80% or more brokers.
Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma
Kite announced it has entered into a clinical trial collaboration with Pfizer Inc. to evaluate the safety and efficacy of the investigational combination of Yescarta (axicabtagene ciloleucel) and Pfizer's utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in patients with refractory large B-cell lymphoma.
1/10/2018Investors and analysts, after all, had been speculating, even nagging, on who the company should buy for several years.
These prominent drug developers look to be enticing buys this month.
Cypralis and Gilead Agree on License Terms Under Which Cypralis Will Hold Exclusive Development and Commercialization Rights to Certain Jointly-Owned 'Cyprolides' for Acute and Chronic Degenerative Diseases
Cypralis and Gilead Sciences have agreed that Cypralis will have exclusive development and commercialization rights to certain macrocyclic inhibitors of peptide bond isomerases, in all fields except for oncology and virology.
12/29/2017Thanks to the Republican tax legislation, pharmaceutical stocks are set to continue their heady northward trajectory in 2018.
It's no secret that the life sciences are increasingly international.